Gazyva

November 26, 2019November 26, 2019

FDA Approves Calquence as Treatment Option for Adults with CLL and SLL

News

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The agency’s decision was based ... Read more

August 16, 2019

Imbruvica Use Expanded in EU to Combo Treatments for Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia

News

The European Commission (EC) has expanded the use of Imbruvica (ibrutinib) to cover combinations with Gazyva (obinutuzumab) for previously untreated adults with chronic lymphocytic leukemia (CLL), and with MabThera (rituximab) for ... Read more

June 25, 2019

Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma

News

Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b trial ... Read more

May 17, 2019

FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients

News

The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia ... Read more

January 31, 2019

FDA Approves Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has approved a combination of Imbruvica (ibrutinib) and Gazyva (obinutuzumab) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This is the first ... Read more

August 3, 2018

Gazyva Infusion Could Be Shorter for Some NHL Patients, Study Finds

News

Shortening the time needed for an infusion of Gazyva (obinutuzumab) did not affect the safety of Japanese patients with previously untreated CD20-positive B-cell non-Hodgkin’s lymphoma, a new study shows. “Safety, tolerability ... Read more

July 11, 2018July 11, 2018

Health Canada OKs Gazyva as First-line Therapy for Advanced Follicular Lymphoma

News

Patients in Canada who have advanced follicular lymphoma now can receive Gazyva (obinutuzumab) in combination with chemotherapy as first-line therapy, Roche Canada announced. Health Canada’s decision follows Gazyva’s approval in the ... Read more

February 13, 2018February 13, 2018

UK Agency Recommends Gazyvaro for First-Line Treatment of Follicular Lymphoma

News

The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended Roche‘s Gazyvaro (obinutuzumab) as a first-line treatment for follicular lymphoma patients, after initially rejecting it. Routine use of ... Read more

December 8, 2017December 8, 2017

Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants

News

Biopharmaceutical company TG Therapeutics and the National Cancer Institute’s SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The ... Read more

November 20, 2017November 20, 2017

FDA Approves Gazyva-Chemo Combo for Advanced Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Roche’s Gazyva (obinutuzumab) in combination with chemotherapy as a first-line treatment for patients with advanced follicular lymphoma. The company said its ... Read more